stars 1 stars 2 stars 3

Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, …) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making.

Physiogenex Questions

The Physiogenex annual revenue was $5 million in 2026.

Thierry Sulpice is the Founder, Chairman, CEO and CSO of Physiogenex.

23 people are employed at Physiogenex.

Physiogenex is based in Escalquens, Occitania.

The NAICS codes for Physiogenex are [54, 5417, 541713, 541, 54171].

The SIC codes for Physiogenex are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users